Mitoconix Bio Company
Mitoconix Bio is pioneering a disease-modifying strategy of improving mitochondrial functions for treating neurodegenerative diseases. Mitoconix’ lead drug is a first-in-class inhibitor of pathological mitochondrial fragmentation and dysfunction with demonstrated in vivo efficacy in animal models of Huntington’s (HD) and Parkinson’s diseases (PD) and beneficial activity in patient-derived cells of HD, sporadic and genetic PD, and sporadic and genetic Alzheimer’s disease (AD).
Technology:
Other
Industry:
Mitochondrial Dynamics
Headquarters:
Israel
Founded Date:
2016
Investors Number:
6
Total Funding:
$54.2M
Estimated Revenue:
Less than $1M
Last Funding Type:
Venture - Series Unknown
Register and Claim Ownership